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Environmental epidemiologyThe quality of exposure assessment is a major determinant of the overall quality of any environmental epidemi-
ology study. The use of biomonitoring as a tool for assessing exposure to ubiquitous chemicals with short phys-
iologic half-lives began relatively recently. These chemicals present several challenges, including their presence
in analytical laboratories and sampling equipment, difﬁculty in establishing temporal order in cross-sectional
studies, short- and long-term variability in exposures and biomarker concentrations, and a paucity of information
on the number of measurements required for proper exposure classiﬁcation. To date, the scientiﬁc community
has not developed a set of systematic guidelines for designing, implementing and interpreting studies of short-
lived chemicals that use biomonitoring as the exposuremetric or for evaluating the quality of this type of research
forWOE assessments or for peer reviewof grants or publications.We describe key issues that affect epidemiology
studies using biomonitoring data on short-lived chemicals and propose a systematic instrument – the Biomoni-
toring, Environmental Epidemiology, and Short-lived Chemicals (BEES-C) instrument – for evaluating the quality
of research proposals and studies that incorporate biomonitoring data on short-lived chemicals. Quality criteria
for three areas considered fundamental to the evaluation of epidemiology studies that include biological mea-
surements of short-lived chemicals are described: 1) biomarker selection and measurement, 2) study design
and execution, and 3) general epidemiological study design considerations. We recognize that the development
of an evaluative tool such as BEES-C is neither simple nor non-controversial. We hope and anticipate that the in-
strument will initiate further discussion/debate on this topic.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).6 Oakdale Avenue, Catonsville,
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Epidemiological research plays a critical role in assessing the effects
of various chemical, physical, biological, radiological, and behavior-
related exposures on human health. However, even well-designed and
rigorously implemented epidemiological studies that are speciﬁcally
designed to test causal hypotheses in humans often report conﬂict-
ing results. Regulatory bodies and consensus panels charged with
recommending health policy typically rely on weight-of-evidencethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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A WOE assessment may be incomplete or misleading if it does not
evaluate study quality to ensure that the conclusions are based on
the strongest evidence available. In addition, study quality assessments
during peer reviews of grant proposals and manuscripts serve to en-
hance the overall quality of human exposure and health research.
While determination of study quality will always to some extent
involve professional judgment, there appears to be an emerging con-
sensus that any evaluation of the strength of epidemiological evidence
should rely on agreed-upon criteria that are applied systematically
(Vandenbroucke et al., 2007). These considerations motivated the de-
velopment and reﬁnement of several study quality assessment tools.
Some of these tools (e.g., STROBE (Vandenbroucke et al., 2007);
CONSORT (Moher et al., 2001)) address general issues that apply across
disciplines. Other tools were developed speciﬁcally for various areas of
medicine or life sciences (e.g., STREGA for genetic studies (Little et al.,
2009), GRADE for comparative treatment effectiveness research
(Owens et al., 2010), and STARD for studies of diagnostic accuracy
(Bossuyt et al., 2004)).
In view of the current tendency toward standardization of WOE as-
sessment that incorporates study quality, the relative paucity of instru-
ments for evaluating environmental epidemiology studies – either
during development of study design or in review of manuscripts – is
notable and difﬁcult to explain. An evaluative scheme focusing on
assessing study quality for weight of evidence assessments (Harmoni-
zation of Neurodevelopmental Environmental Epidemiology Studies)
(Youngstrom et al., 2011) used the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) as the basis for a coding tool (Whiting
et al., 2003), but as the name implies, this instrument centered on
neurodevelopmental studies. TheNational Toxicology Program recently
developed an approach for assessing study quality (NTP, 2013) and
used this to examine the literature on environmental chemicals and di-
abetes (Kuo et al., 2013); this scheme included assessments of both ep-
idemiologic and toxicology literature and included non-persistent and
persistent chemicals but did not incorporate issues speciﬁc to biomoni-
toring of short-lived chemicals.
The lack of a tool that provides systematic guidance on best practices
for environmental epidemiological research is an important limitation
to regulatory decisions which rely on population-based studies. WOE
assessments based on environmental epidemiology data are unique be-
cause, unlike other areas of research, experimental studies designed to
elicit an adverse outcome in humans are rarely, if ever, ethically possible.
Thus, environmental epidemiology studies are almost always observa-
tional and are subject to unavoidable uncertainty stemming from various
sources. An important source of uncertainty in environmental epidemiol-
ogy, but also an area of rapid progress, relates to exposure science.
Exposure assessment is a major determinant of the overall data
quality in any environmental epidemiology study (Hertz-Picciotto,
1998), including chemicals with short physiologic half lives. Short-
lived chemicals are those for which the time required to eliminate
one-half of the chemical mass from the body or from a given matrix is
on the order ofminutes to hours or days. The quality of the exposure as-
sessment for short-lived chemicals is intimately tied to the data's utility
in assessing associations with health outcomes as well as to studies
using biomonitoring to examine various aspects of exposure. In recent
years, exposure science methods have particularly beneﬁted from im-
provements in the ability to detect environmental chemicals through
biomonitoring. Biomonitoring is the measurement of chemicals in vari-
ous humanmatrices such as blood, urine, breath,milk andhair. Biomon-
itoring data integrate exposure from all routes (oral, inhalation, dermal,
trans-placental) and are valuable for: (1) establishing population refer-
ence ranges; (2) identifying unusual exposures for subpopulations;
(3) evaluating temporal variability and trends within a population;
(4) validating questions designed to estimate individual exposure;
and (5) examining associations with health outcomes in epidemiologic
studies.Epidemiologic research with biomonitoring as the basis for measur-
ing exposure for persistent organic pollutants andmetals has been con-
ducted for decades. By contrast, biomonitoring of ubiquitous chemicals
with short physiologic half-lives (e.g., benzene, phthalates, certain pes-
ticides) began relatively recently, and these chemicals present several
new challenges as interpretation of data on these chemicals is compli-
cated by variability in exposure and the ubiquitous nature of many of
these chemicals, including in analytical laboratories and sampling
equipment. These chemicals also present challenges when selecting
the matrix to be used in the research. To date, the scientiﬁc community
has not developed a set of systematic guidelines for implementing and
interpreting biomonitoring studies of these chemicals. Similarly, there
is nopublishedmethod for evaluating thequality of this type of research
for WOE assessments or for peer review of grants or publications.
This knowledge gap was the speciﬁc focus of the 2013 international
workshop “Best Practices for Obtaining, Interpreting and Using Human
Biomonitoring Data in Epidemiology and Risk Assessment: Chemicals
with Short Biological Half-Lives.” The workshop brought together
an expert panel from government, academia, and private institutions
specializing in analytical chemistry, exposure and risk assessment, epi-
demiology, medicine, physiologically-based pharmacokinetic (PBPK)
modeling, and clinical biomarkers. The aims of the workshop were to
(i) describe the key issues that affect epidemiology studies using bio-
monitoring data on chemicals with short physiologic half lives, and
(ii) develop a systematic scheme for evaluating the quality of research
proposals and studies that incorporate biomonitoring data on short-
lived chemicals.
Quality criteria for three areas considered to be fundamental to the
evaluation of epidemiology studies that include biological measure-
ments of short-lived chemicals are described in this paper: 1) biomarker
selection andmeasurement, 2) study design and execution, and 3) gen-
eral epidemiological study design considerations. Key aspects of these
topic areas are discussed and are then incorporated into a proposed
evaluative instrument – the Biomonitoring, Environmental Epidemiolo-
gy, and Short-Lived Chemicals (BEES-C) instrument – organized as a
tieredmatrix (Table 1). Some aspects of the proposed evaluative instru-
ment include study design elements that are relevant to epidemiology
studies of both persistent and short-lived chemicals. In fact, aspects of
widely accepted instruments such as STROBE have intentionally been
weaved into the evaluative instrument proposed here (Gallo et al.,
2011; Little et al., 2009; Vandenbroucke et al., 2007). (STROBE offers
guidance regardingmethods for improving on reporting of observation-
al studies and for critically evaluating these studies; STROBE is designed
to be used by reviewers, journal editors and readers [(Vandenbroucke
et al., 2007)].) While both established and novel aspects of this instru-
ment are critical to assessing the quality of a study using biomonitoring
of short-lived chemicals as an exposure assessment approach, the pri-
mary objective of this communication is to cover critical aspects of stud-
ies of short-lived chemicals; these are described more fully in the text.
The list of quality issues that could be used to evaluate a given study
is long; a tension exists between the development of an all-inclusive but
unwieldy instrument versus a more discriminating and utilitarian in-
strument that includes only the most important issues (focusing on
those research aspects that are unique – or of particular importance –
to short-lived chemicals).We opted for the latter in developing the pro-
posed BEES-C Instrument. The instrument can be applied to studies that
examine the relation between exposure and health outcome as well as
to studies using biomonitoring data to various aspects of exposure
(e.g., temporal and spatial trends). The issues raised here and addressed
by the BEES-C instrument cut acrossmultiple disciplines that involve bi-
ological measurements of short-lived chemicals, including occupational
studies and nutritional epidemiology.
The features of short-lived chemicals in environmental epidemiolo-
gy studies that require special attention are: the number and timing of
samples taken in order to represent the relevant exposure window for
the health outcome of interest; the ubiquitous use of many of these
Table 1
Biomonitoring, Environmental Epidemiology, and Short-lived Chemicals (BEES-C) instrument: Evaluative instrument for assessing quality of epidemiology studies involving biomonitor-
ing of chemicals with short physiologic half-lives. Evaluative criteria cover several aspects of environmental epidemiology researchwith biomonitoring as the exposuremetric (acronyms
deﬁned at bottom of table). The justiﬁcation column is used to increase transparency in the process of decision-making.
Study assessment
components
TIER 1 TIER 2 TIER 3 Justiﬁcation
Biomarker selection and measurement
Biological relevance
(Parent/surrogate
relationship)
Exposure biomarker Biomarker in a speciﬁed matrix has accurate and
precise quantitative relationship with external
exposure, internal dose, or target dose.
Evidence exists for a relationship
between biomarker in a speciﬁed matrix
and external exposure, internal dose, or
target dose.
Biomarker in a speciﬁed matrix is a poor
surrogate (low accuracy and precision)
for exposure/dose.
Effect biomarker Bioindicator of a key event in an AOP. Biomarkers of effect shown to have a
relationship to health outcomes but the
mechanism of action is not understood.
Biomarker has undetermined
consequences (e.g., biomarker is not
speciﬁc to a health outcome).
Speciﬁcity Biomarker is derived from exposure to one parent
chemical.
Biomarker is derived from multiple
parent chemicals with similar adverse
endpoints.
Biomarker is derived from multiple
parent chemicals with varying types of
adverse endpoints.
Method sensitivity
(detection limits)
Limits of detection are low enough to detect
chemicals in a sufﬁcient percentage of the
samples to address the research question.
NA Frequency of detection too low to
address the research hypothesis.
Biomarker stability Samples with a known history and documented
stability data or those using real-time
measurements.
Samples have known losses during
storage but the difference between low
and high exposures can be qualitatively
assessed.
Samples with either unknown history
and/or no stability data for analytes of
interest.
Sample contamination Samples are contamination-free from time of
collection to time of measurement (e.g., by use of
certiﬁed analyte-free collection supplies and
reference materials, and appropriate use of blanks
both in the ﬁeld and lab). Research includes
documentation of the steps taken to provide the
necessary assurance that the study data are reliable.
Study not using/documenting these
procedures.
There are known contamination issues
and no documentation that the issues
were addressed.
Method requirements Instrumentation that provides unambiguous
identiﬁcation and quantitation of the biomarker
at the required sensitivity (e.g., GC–HRMS,
GC–MS/MS, LC–MS/MS).
Instrumentation that allows for
identiﬁcation of the biomarker with a
high degree of conﬁdence and the
required sensitivity (e.g., GC–MS,
GC–ECD).
Instrumentation that only allows for
possible quantiﬁcation of the biomarker
but the method has known interferants
(e.g., GC–FID, spectroscopy).
Matrix adjustment Study includes results for adjusted and non-
adjusted concentrations if adjustment is needed.
Study only provides results using one
method (matrix-adjusted or not).
No established method for adjustment
(e.g., adjustment for hair)
Study design and execution
Temporality Established time order between exposure and
outcomes; relevant interval between the
exposure and the outcome or reconstructed
exposure and appropriate consideration of
relevant exposure windows.
Established time order between
exposure and outcome, but no
consideration of relevant exposure
windows.
Study without an established time order
between exposure and outcome.
Exposure variability
and misclassiﬁcation
Sufﬁcient number of samples.
Error considered by calculating measures of
accuracy (e.g., sensitivity and speciﬁcity) and
reliability (e.g., ICC).
If one sample is used, there is evidence that errors
from a single measure are negligible.
More than one sample collected, but
without explicit evaluation of error.
Exposure based on a single sample
without considering error.
General epidemiological study design considerations
Study rationale Studies designed speciﬁcally to evaluate an a
priori formulated hypothesis.
Studies using existing samples or data to
evaluate an a priori formulated
hypothesis.
Data mining studies without a
pre-speciﬁed hypothesis; multiple
simultaneous hypothesis testing.
Study participants Population-based unbiased selection protocol;
high response rate and/or low loss to follow-up.
Population-based unbiased selection
protocol; low response rate and/or high
loss to follow-up.
Methods of sample selection, and
response/loss to follow-up rates are not
reported.
Data analysis Clear distinction between causal and predictive
models; adequate consideration given to
extraneous factors with assessment of effect
modiﬁcation and adjustment for confounders;
sensitivity analyses.
Adequate consideration of extraneous
factors, but without sensitivity analyses.
Inadequate control for extraneous
factors.
Reporting Study clearly states its aims and allows the reader
to evaluate the number of tested hypotheses (not
just the number of hypotheses for which a result
is given). If multiple simultaneous hypothesis
testing is involved, its impact is assessed,
preferably by estimating PFP or FP:FN ratio. There
is no evidence of outcome reporting bias, and
conclusions do not reach beyond the observed
results.
Conclusions appear warranted, but the
number of tested hypotheses is unclear
(either not explicitly stated or difﬁcult
to discern) and/or there is no
consideration of multiple testing.
Studies that selectively report data
summaries and lack transparency in
terms of methods or selection of
presented results.
AOP = adverse outcome pathways; FP = false positive; FN = false negative; GC–HRMS = gas chromatography/high-resolution mass spectrometry; GC–MS = gas chromatography/
mass spectrometry; GC–ECD = gas chromatography–electron capture detector; GC–FID = gas chromatography–ﬂame ionization detector, ICC = intra-class correlation coefﬁcient;
NA = not applicable; PFP = probability of false positive.
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products, laboratory equipment, dust, food, etc., which introduces spe-
cial needs for avoidance of sample contamination; choice of appropriate
biologicalmatrix; and the ability tomeasure a large number of chemicals
in one sample, increasing the need for attention to full reporting and is-
sues related to multiple comparisons. These are discussed more fully in
the following sections, with examples given for each issue. While most
of the instrument topics pertain to biomarkers of exposure, biomarkers
of effect are described when relevant.
2. Using the BEES-C instrument
The BEES-C instrument can serve multiple purposes including:
aiding researchers in the development of study design, reviewing
grant proposals, peer reviewing manuscripts, and conducting WOE
assessments.
2.1. Intended uses of BEES-C
The ultimate goal of the BEES-C tool is to assist researchers in im-
proving the overall body of literature on studies of short-lived chemicals
in humans. The BEES-C instrument is not intended to be used: (i) to dis-
courage researchers from conducting hypothesis-generating research,
or (ii) to preclude lower-tiered studies from being included in WOE
assessments.
As with any type of evaluative instrument, professional judgment
must be part of the evaluative process, both in terms of tiering and for
determining which aspects of the instrument are relevant to a given
study.
In the sections below, we describe the key aspects of BEES-C along
with examples. Here we discuss recommendations for utilizing BEES-
C. While the preponderance of the topics covered by this instrument
would pertain to human biomonitoring studies that are part of epi-
demiological research on associations between biomarkers of expo-
sure and somemeasure of effect (e.g., biomarker of effect, physician-
diagnosed disease), only a portion of the BEES-C instrument will be
applicable to human biomonitoring studies designed for other purposes
(e.g., exposure assessment for temporal or spatial trend analysis).
2.2. How to use BEES-C
Table 1 is organized according to aspects of study design (rows) and
evaluative tiers (columns). For each study under review, critical aspects
are assessed row by row and the appropriate cell is color-coded (Fig. 1),
with Tier 1 indicating the highest quality. This allows the researcher/
reviewer to obtain an overall picture of study quality. The user of this
instrument should provide justiﬁcation for each decisionmade (Table 1);
this will enhance transparency in the process. The BEES-C instrument can
be used: (i) as an instrument by researchers evaluating their proposed
study design to ensure that the study quality is maximized; (ii) by re-
viewers ofmanuscripts andpublications to systematically assess the qual-
ity of the research and identifying areaswhere quality could be improved;
(iii) by those performing systematic reviews for evaluating study quality
in order to inform decision-making (e.g., Is a study of sufﬁciently high
quality to use in developing regulatory standards? Should a study be in-
cluded in a meta-analysis?); and (iv) by others wishing to incorporate
BEES-C into their currently existing review schemes. For example, many
of the issues in our proposed approach that are speciﬁcally applicable to
short-lived chemicals are not yet part of the draft Ofﬁce of Health Assess-
ment and Translation Approach (NTP, 2013) but could be incorporated
into their approach for conducting “literature-based evaluations to assess
the evidence that environmental chemicals, physical substances, or mix-
tures (collectively referred to as “substances”) cause adverse health
effects.”
Implicit in this study quality evaluative instrument is that the man-
uscript or proposal will explicitly report on each of the issues below. Inotherwords, in order to assesswhether the studymeets the criteria for a
given tier, the information on that issue must be clearly described. For
studies relying on previously-published biomonitoring data (e.g., US
National Health and Nutrition Examination Survey [NHANES]), the
same reporting requirements must be met. Authors should be explicit
in their description of methods, including pertinent details such as
limit of detection for the study, relative standard deviation and relevant
quality control parameters.
The lack of numeric scoring for this process is intentional. There will
no doubt be instances where a study is of high quality for most compo-
nents, but has not addressed a key issue that substantially reduces con-
ﬁdence in the study results. An overall high “score” would mask this
problem. Instead, we propose a qualitative approach that increases
ﬂexibility.
A ﬁnal note:We are unaware of studies thatwould be categorized as
Tier 1 for all aspects of the evaluation.While a study that falls into Tier 1
for all aspects is certainly a goal and would provide robust data, it is the
case that most studies will contain aspects that would be considered
Tier 2 or 3. Depending on the users' intent for the study data, this may
not be problematic for certain evaluative issues. On the other hand,
there are some issues for which a Tier 3 designation would render the
study of low utility (e.g., inability to demonstrate samples were free of
contamination).
3. Components of BEES-C
We ﬁrst describe BEES-C components speciﬁcally related to short-
lived biomarkers. This is followed by aspects of BEES-C that pertain to
more general epidemiological study design issues.
3.1. Biomarker selection and measurement
A biomarker/biological marker has been deﬁned as an “indicator of
changes or events in biological systems. Biological markers of exposure
refer to cellular, biochemical, analytical, or molecular measures that are
obtained frombiologicalmedia such as tissues, cells, or ﬂuids and are in-
dicative of exposure to an agent” (Zartarian et al., 2005). Thus, bio-
markers can be used to assess exposure to a chemical by measuring
the amount of that chemical or its metabolite in the body. In addition,
biomarkers can be used as indicators of health effects.Many biomarkers
of exposure and effect are short-lived, and both types of biomarkers are
commonly used in human research on exposure to – and health effects
from – environmental chemicals. While this evaluative tool is predom-
inantly focused on biomarkers of exposure, many of the principles elu-
cidated here also apply to biomarkers of effect.
As a general rule, studies designed to observe associations between
exposure and health effects are more defensible if appropriate and
well-established biomarkers are used as exposure and/or health end-
point surrogates. There is general consensus on certain criteria that
should be met for biomarkers to be considered high-quality (NRC,
2006; Zelenka et al., 2011). Some of these criteria are based on the
inherent qualities of the biomarkers (e.g., its relevance to chemical ex-
posure and/or biological relevance). Other criteria pertain to the mea-
surement of the biomarker — that is, the accuracy and precision of
methods used to quantify the biomarker, the stability of the biomarker
during storage, the possibility for sample contamination leading to er-
rors in biomarker quantitation, and the need to adjust for biological ma-
trix effects that might introduce measurement error. Critical aspects of
biomarker selection and measurement are described in the following
subsections and the proposed tiering scheme for BEES-C is shown in
Table 1.
3.1.1. Relevance
Source-to-outcome continuums are frequently used to demonstrate
the path of a chemical from generation, to human contact, to target dose
and subsequent molecular, cellular, organ, organism, and population
Hypothetical Study 1 Hypothetical Study 2
STUDY 
ASSESSMENT 
COMPONENTS
TIER 1 TIER 2 TIER 3
Biomarker Selection and Measurement
Biological relevance 
Exposure biomarker 
Effect biomarker
Specificity
Method sensitivity
Biomarker stability
Sample contamination
Method requirements
Matrix adjustment
Study Design and Implementation
Temporality
Exposure variability 
and misclassification
General Epidemiological Study Design 
Considerations
Study rationale
Study participants 
Reporting
Data analysis
STUDY 
ASSESSMENT 
COMPONENTS
TIER 1 TIER 2 TIER 3
Biomarker Selection and Measurement
Biological relevance
Exposure biomarker
Effect biomarker
Specificity
Method sensitivity
Biomarker stability
Sample contamination
Method requirements
Matrix adjustment
Study Design and Implementation
Temporality
Exposure variability 
and misclassification
General Epidemiological Study Design 
Considerations
Study rationale
Study participants 
Reporting
Data analysis
Fig. 1. Example of quality comparison of two hypothetical studieswith biomonitored short-lived chemicals using the BEES-C instrument. For each hypothetical study under review, critical
aspects are assessed row by row and the appropriate cell is color-coded, allowing the researcher/reviewer to obtain an overall picture of study quality. Text in cells has been removed for
readability.
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characterize exposure, dose, and biological response. In this section
we consider both biomarkers of exposure (i.e., a parent chemical,
metabolite, or interaction product at a target (WHO, 2001)) and bio-
markers of effect (i.e., a measureable biochemical or physiological al-
teration that is associated with a health outcome (WHO, 2001)) as
important components of epidemiological studies of associations be-
tween exposure and health outcome.
3.1.1.1. Biomarkers of exposure. Epidemiologic research can be hypothesis-
driven or more geared toward hypothesis-generation. In the latter case,
the most suitable biomarker of exposure is one that is an accurate and
precise surrogate of external exposure or internal dose.When a strong bi-
ological rationale exists, and a biological “target” is known, themost suit-
able biomarker is one that is directly measured at the target (molecular,
cellular, or organ level), or is an accurate and precise surrogate of target
dose.
Ideally, a clear understanding of the quantitative linkages between
exposure, dose, and biomarker levels will exist for any biomarker that
is used in an epidemiological study. Considering the invasive nature of
target tissue sampling, most biomarker-based epidemiological studies
utilize samples of blood, urine, hair, or other easily-accessible matrices.
Elucidating quantitative relationships between biomarker measure-
ments from these matrices and exposure/dose levels requires an un-
derstanding of chemical absorption, distribution, metabolism, and
elimination (ADME); these processes are frequently described using
pharmacokinetic (PK) models, or physiologically-based pharmacoki-
netic (PBPK) models. Prior to the use of biomarkers in an epidemiolog-
ical study, a solid understanding of chemical ADME should exist, aswell
as the intrinsic (e.g., genetics, life-stage, pregnancy, gender) and extrin-
sic (e.g., diet, medication, medical conditions) factors that are likely to
affect ADME. Furthermore, for short-lived biomarkers, it is important
to know speciﬁc timing details (e.g., time of day, time since last meal
for those chemicals associated with dietary exposure, time since last
urine void) in relation to sample collection. Ideally, the relationships be-
tween biomarker concentration and exposure/dose levels, and theeffects of intrinsic, extrinsic, and timing factors on these relationships,
will be thoroughly evaluated before the biomarker is used in an epide-
miological study. Critical information that is needed to properly inter-
pret the biomarker (with respect to exposure/dose) should then be
collected and carefully evaluated as part of the study. The costs and ben-
eﬁts of each biomarker of exposure should be carefully examined and
interpreted as part of any epidemiological evaluation.
It is important to note thatmatrix selection is an integral component
of exposure and/or epidemiology research, andmultiple factorsmust be
considered including measurement capability, contamination issues,
and target analyte association with exposure or health outcome. BEES-
C addresses each of these issues separately.
3.1.1.1.1. Short-lived chemical example. Bisphenol A (BPA) is mea-
sured in urine in the free form (parent), as sulfate- or glucoronide-
bound conjugates, or as a combination (total BPA) of the free and conju-
gated forms (Harthé et al., 2012; LaKind et al., 2012a; Völkel et al., 2008;
Ye et al., 2005). Several recent studies have examined endocrine-related
health outcomes associated with BPA exposure. The most biologically-
relevant biomarker is the free (parent) BPA, because only parent BPA
is considered active in terms of estrogenicity (EPA, 2013; WHO, 2011).
The quantiﬁcation of free BPA in urine is analytically challenging, how-
ever, as only a small fraction of BPA is present in the non-conjugated
form (Ye et al., 2005). Given this limitation, measurements of conjugat-
ed or total BPAmay be useful surrogates of free BPA. Speciﬁcally, if there
is small variation in the ratio of free to conjugated BPA within and be-
tween individuals (with respect to the variation in exposure levels),
then conjugated or total BPA may be an accurate and precise surrogate
of free BPA, and of BPA exposure in general. This example underscores
the importance of understanding relationships between exposure and
biomarkers, different types of biomarkers (parent vs. metabolites in
their respective matrices), and biomarkers and biological targets, while
ensuring that the appropriate research question is addressed. It further
highlights the possibility of trade-offs when selecting an individual bio-
marker of exposure (for BPA, biological relevance could be optimized at
the expense of ability to detect the chemical).
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a speciﬁedmatrix is an accurate and precise surrogate of target dose (for
hypothesis-driven studies with a known target) or of external exposure
(for studies without a known target). For a Tier 2 biomarker, evidence
exists for a relationship between the biomarker in a speciﬁed matrix
and external exposure, internal dose, or target dose. A Tier 3 biomarker
in a speciﬁedmatrix is a poor surrogate (low accuracy and precision) for
exposure/dose.
3.1.1.2. Biomarkers of effect. It can be challenging in epidemiological
studies to perform meaningful comparisons of short-lived biomarker
measurements and long-term health outcomes. Particularly in cross-
sectional studies, a key assumption is that current biomarker levels re-
ﬂect past exposures during timewindows thatwere relevant for disease
onset. Biomarkers of effect offer ameans to evaluate exposure–response
relationships in target populations, during critical time windows, prior
to disease onset. Findings are interpreted based on the strength of asso-
ciation between biomarkers of exposure and effect, and between bio-
markers of effect and the adverse health outcome.
The progression from an exposure event to an adverse health effect
can be deﬁned using adverse outcome pathways (AOPs) (Ankley et al.,
2010). The AOP for a particular health outcome beginswith a molecular
initiating event at a target within the body. Effects at the molecular tar-
get, initiated by exposure events, progress to effects at the cellular, tis-
sue, and organ levels, and ultimately to the whole organism. “Key
events” are intermediate steps along the AOP that can be experimental-
ly monitored to evaluate progression along the AOP. Measurements of
these key events in accessible biological media from living intact organ-
isms are called bioindicators. Bioindicators are considered ideal bio-
markers of effect because they reﬂect a biological function linked to a
speciﬁc adverse outcome; they “provide a high degree of conﬁdence
in predicting the potential for adverse effects in an individual or popula-
tion” (www.epa.gov/pesticides/science/biomarker.html). Biomarkers of
effect categorized as “Undetermined Consequences” reﬂect a less
certain pathway linking alterations to any speciﬁc disease outcome
(www.epa.gov/pesticides/science/biomarker.html). Predictions of
outcomes therefore, for either individuals or populations, are less
certain when using these biomarkers in place of bioindicators.
3.1.1.2.1. Study evaluation (Table 1). A Tier 1 biomarker of effect is a
bioindicator of a key event in an AOP. A Tier 2 biomarker of effect has
been shown to have a relationship to health outcomes but the mecha-
nism of action is not understood. Biomarkers of effect that have unde-
termined consequences are considered Tier 3.
3.1.2. Speciﬁcity
A single biomarker of exposuremay be derived frommultiple parent
chemicals, making assessments of exposure to the parent chemical dif-
ﬁcult to ascertain (Barr and Needham, 2002; Barr et al., 1999, 2006). In
terms of exposure assessment and interpretation of epidemiological re-
search, this is especially problematic if the parent chemicals have differ-
ent toxicities or modes of action. Further, an example of interference
with assessing exposure to a parent chemical is the situation in which
one of the metabolites also can be found in the environment (an exog-
enous source).
3.1.2.1. Short-lived chemical example. 3-phenoxybenzoic acid (3PBA) is
an example of a short-lived chemical that highlights the importance of
evaluation of speciﬁcity when assessing study quality. 3PBA is a metab-
olite of at least 18 synthetic pyrethroids (Barr et al., 2010; Leng et al.,
1997) and is also a potential metabolite of the 3PBA environmental
degradate 3-phenoxybenzyl alcohol. Thus, urinary 3PBAmeasurements
represent exposure to multiple insecticides with varying degrees of
neurotoxicity, in addition to exposure to an environmental degradate
that is not known to be neurotoxic (Barr et al., 2010). Urinary 3PBA
measurements can therefore provide a conservative estimate of pyre-
throid exposure; however, it likely would not provide an accurateexposure estimate for neurotoxic effects related to pyrethroid insecti-
cide exposure in the absence of additional exposure data. Thus, ﬁnding
a relation between neurotoxicity and exposure would be more difﬁcult
since the true exposures are unknown.
3.1.2.2. Study evaluation (Table 1). A Tier 1 study includes a biomarker of
exposure that is derived from exposure to one parent chemical. A Tier 2
study includes a biomarker derived from multiple parent chemicals
with similar types of adverse endpoints. A Tier 3 study includes a bio-
marker derived from multiple parent chemicals with varying types of
adverse endpoints.
3.1.3. Method sensitivity
The biomarker should be appreciably present in thematrix being an-
alyzed (Calafat and Needham, 2008). A biomarker that is frequently
non-detectable in a matrix – irrespective of exposure – is undesirable
in environmental epidemiologic research as the results may be of limit-
ed utility.
3.1.3.1. Short-lived chemical example. Several polycylic aromatic hy-
drocarbons (PAHs) with four or more rings are suspected or known
human carcinogens (e.g., benzo[a]pyrene). Standard analytical methods
(e.g., GC–MS [gas chromatography/mass spectrometry] or LC–MS/MS
[liquid chromatography–tandemmass spectrometry]) are often not suf-
ﬁciently sensitive for quantifyingmetabolites of these PAHs in accessible
media (e.g., urine) (Bouchard and Viau, 1997), thus hindering epidemio-
logical investigations. Biomarkers of smaller PAHs, including naphtha-
lene, phenanthrene and pyrene, have been evaluated as surrogates of
the larger carcinogenic species (Bouchard et al., 1998; Sobus et al.,
2009; Viau et al., 1999; Withey et al., 1991). These surrogates offer a
means to overcome analytical limitations, but must be thoroughly eval-
uated for their ability to reﬂect exposure to the target species, to gauge
co-occurrence among the PAHs, and to evaluate information on corre-
lates of exposure sources.
3.1.3.2. Study evaluation (Table 1).A Tier 1 studymethodhas limits of de-
tection low enough to detect chemicals in a sufﬁcient percentage of the
samples to address the research question (e.g., 50–60% detectable
values if the research hypothesis requires estimates of both central ten-
dencies and upper tails of the population concentrations) (Barr et al.,
2010; Zota et al., 2014). There is no Tier 2 for this component. A Tier 3
study has too low a frequency of detection to address the research
hypothesis.
3.1.4. Biomarker stability
The biomarker should be stable in a given matrix over the time of
storage and use (Barr et al., 2005a). Stability of the sample should be
documented. Studies using samples that have undergone freeze/thaw
cycles should demonstrate the stability of those samples. Time from col-
lection of sample to measurement should be documented.
3.1.4.1. Short-lived chemical example.While persistent organic pollutants
are usually stable in blood products stored indeﬁnitely if frozen at
−20 °C or below, non-persistent chemicals may be less stable in
blood. For example, current-use pesticides are highly reactive and can
easily degrade in blood enzymatically (Barr et al., 1999). Blood pre-
served with EDTA minimizes esterase activity but the measurement
should bemadewithin a fewmonths after collection. Thaw/refreeze cy-
cles or thawing samples in hot water can also cause degradation. The
use of long-archived urine or blood samplesmay provide data on histor-
ically collected samples (e.g., NHANES III samples) butmany have expe-
rienced thaw/refreeze cycles that can result in degradation of sensitive
chemicals or contamination of the sample itself. Small, multiple aliquots
of a single sample should be stored to be able to conﬁrm the stability of
historic samples. Losses of biomarkers can also occur from binding
to the walls of the containers and from volatilization. While plastic
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glass, they can be a source of contamination of some chemicals. In addi-
tion, they can absorb both metals and organic compounds resulting in
underestimation of chemical concentration. Storage studies using
spiked matrices at levels consistent with those expected to be found
in the actual sample or the addition of stable isotopically labeled com-
pounds to samples prior to storage should be done to validate that
there are no losses during storage or in thaw–refreeze cycles.
3.1.4.2. Study evaluation (Table 1). A Tier 1 study would include samples
with a knownhistory and documented stability data. Tier 2 studies have
known losses during storage but the difference between low and high
exposures can be qualitatively assessed (i.e., for the purposes of the
study, it is sufﬁcient to bin study participants as having either low or
high exposure). Tier 3 studies use sampleswith either unknown history
and/or no stability data for the analyte(s) of interest.
3.1.5. Sample contamination
This BEES-C evaluative criterion is one of themost critical criteria for
evaluating studies measuring ubiquitous short-lived chemicals. This is
because the likelihood of sample contamination from the time of collec-
tion to the time of measurement has been demonstrated for many of
these chemicals, this in spite of great lengths taken to avoid contamina-
tion. A wide range of chemicals with short physiologic half lives are
not only environmentally ubiquitous but may also be present in the
sampling and analytical equipment used in epidemiological research.
Thus, extreme care is necessary in order to avoid/prevent sample con-
tamination during all phases of a study from sample collection to sam-
ple measurement (Barr et al., 1999; Calafat and Needham, 2008, 2009;
Needham et al., 2007). During sample collection, supplies containing
the target chemical or exposing the collectionmaterials ormatrix to en-
vironmental media (e.g., air or water) can falsely elevate the measured
concentrations. Even with precautions, studies have reported difﬁcul-
ties with analytic contamination, contributing to uncertainty in inter-
pretation of study results.
3.1.5.1. Short-lived chemical example. Ye et al. (2013) note that despite
their best efforts, samples at the Centers for Disease Control Prevention
laboratorywere contaminatedwith triclosan; the source of the contam-
ination was ultimately identiﬁed as a triclosan-containing handsoap
used by a technician. Similarly, several research groups have noted the
difﬁculties in attempting to measure BPA in blood samples, in part,
because of contamination (including in solvents and reagents) despite
great care taken to avoid such contamination (Calafat et al., 2013;
Markham et al., 2010; Teeguarden et al., 2011; Ye et al., 2013).
3.1.5.2. Study evaluation (Table 1).A Tier 1 study ensures the samples are
contamination-free from time of collection to time of measurement
(e.g., by use of certiﬁed analyte-free collection supplies and reference
materials, and appropriate use of blanks both in the ﬁeld and lab). The
research will include documentation of the steps taken to provide the
necessary assurance that the study data are reliable and accurate. Any
study not using/documenting these procedures is categorized as Tier
2. In a Tier 3 study, there are known contamination issues and no docu-
mentation that the issues were addressed.
3.1.6. Method requirements
The quality of a biomarker for assessing exposure is largely depen-
dent upon the quality of the method used for measurement. This can
be a difﬁcult aspect of biomarker measurement to evaluate. For exam-
ple, a laboratory's participation and success in a proﬁciency testing exer-
cisemay seem to be a reasonable test for a Tier 1 study; however, many
proﬁciency testing studies have tolerance ranges that can vary by 200%
(i.e., an “acceptable” analyte concentration value can be +/−200% of
the true value). In general, the study methods should have appropriate
instrumentation and describe the accompanying procedures (e.g., QC,method robustness, presence of conﬁrmation ions, use of isotope
dilution).
3.1.6.1. Study evaluation (Table 1). A Tier 1 study includes instru-
mentation that provides unambiguous identiﬁcation and quantita-
tion of the biomarker at the required sensitivity (e.g., GC–HRMS
[gas chromatography/high-resolution mass spectrometry], GC–MS/
MS, LC–MS/MS). A Tier 2 study uses instrumentation that allows for
identiﬁcation of the biomarker with a high degree of conﬁdence and
the required sensitivity (e.g., GC–MS, GC–ECD [gas chromatography-
electron capture detector]). A Tier 3 study uses instrumentation that
only allows for possible quantiﬁcation of the biomarker but themethod
has known interferants (e.g., GC–FID [gas chromatography–ﬂame ioni-
zation detector], spectroscopy).
3.1.7. Matrix adjustment
Biomarkers are most commonly measured and reported in units of
concentration; that is, mass of biomarker/volume of biological media.
There are strong effects of variable urine output (driven by diet, exercise,
hydration, age, disease state, etc.) on urinary biomarker concentration,
and of blood volume and fat content on blood biomarker concentration.
Urine biomarker concentrations have beennormalized across andwithin
subjects to correct for variable urine dilution using creatinine concentra-
tion (derived from creatine phosphate breakdown in muscle), speciﬁc
gravity, urine output, and other methods, though uncorrected urinary
levels in spot samples without auxiliary information are commonly re-
ported andutilized in assessments of exposure and relationship to health
outcomes (Barr et al., 2005b; LaKind and Naiman, 2008, 2011; Lorber
et al., 2011; Meeker et al., 2005). There is no current consensus on the
best method(s) for “correcting” urinary biomarkers measurements
for variable urine dilution. Minimally, both the volume-based and a
corrected (creatinine and/or other method) concentrations should be
provided to allow appropriate comparison across studies. It is also in-
structive to obtain a full volume void and elapsed time between voids.
Blood-based biomarker levels have been reported in whole blood,
serum, plasma and as lipid-adjusted values. The method used to deter-
mine the lipid correction or to separate the different components of the
blood ﬂuid should be provided and all concentrations, when available,
should be reported (e.g., whole volume and lipid-adjusted). Similarly,
issues related to fasting samples and serum lipid adjustment in mea-
sures of lipophilic chemicals must be considered (Schisterman et al.,
2005). The validity of lipid and other tissue component adjustments
have not been established for certain short-lived chemicals such as cur-
rent use pesticides. In these instances, the whole-volume concentra-
tions and adjusted concentrations should be reported with a notation
that adjustment validity has not been established. In addition, plasma
volume increases in pregnancy (and may also increase for some pre-
existing diseases or underlying health conditions) and may also need
to be considered when comparing plasma concentrations across preg-
nancy or populations (Hytten, 1985).
Information about the sample collection requirements and matrix
treatment is important when comparing data across studies or to refer-
ence ranges. Studies by different governmental agencies (e.g., the
European Union, speciﬁc European countries, US NHANES, Canadian
Health Measures Survey, Consortium to Perform Human Biomonitoring
on a European Scale, state-based HANES) and other large biomonitoring
data repositories may have different protocols for collecting and pro-
cessing samples that can alter the matrix and reported biomarker con-
centrations. For example, instructions given to the participant about
fasting prior to sample collection can minimize the lipid content in
blood thusminimizing a lipophilic biomarker concentration in a sample
(Barr et al., 2005a), and these instructions are not necessarily the same
from country to country (LaKind et al., 2012a). Similarly, a ﬁrst morning
urine voidmay bemore concentrated inmatrix components than a sim-
ple spot sample whichmay alter our ability to detect or differentiate an
analyte (Kissel et al., 2005; Scher et al., 2007). Further, ﬁrst morning
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the relationship between previous exposure and sample collection and
measurement; this is especially important for chemicals for which diet
is a predominant route of exposure as the void would be collected
after overnight fasting. Blood plasma collected with EDTA versus hepa-
rin as an anticoagulant may alter the properties of the matrix (Barr
et al., 2005a). Differences in collection requirements and sample pro-
cessing (as well as health conditions of study participants – such as
kidney disease – that could affect biomarker concentrations) need
to be reported, considered and weighed accordingly when results are
compared across studies.
3.1.7.1. Study evaluation (Table 1). We recognize that the best practice
for matrix adjustment is intimately associated with the hypothesis to
be tested and the speciﬁc chemical of interest, and that consensus in
this area has not yet been reached. However, adjustment can have a sig-
niﬁcant effect on study outcome. We therefore propose that a Tier 1
study would provide results for adjusted and non-adjusted concentra-
tions (if adjustment is needed), thereby allowing the reader to reach
their own conclusions about the impact of matrix adjustment. A Tier 2
study is one that only presents the results using one method (matrix-
adjusted or not). A Tier 3 study includes measurements of a chemical
in a matrix that does not yet have a validated adjustment method.
3.2. Study design and execution
Considerations of both study design and exposure variability and
misclassiﬁcation are especially important for short-lived chemicals.
3.2.1. Epidemiology study design
Studies that explore associations between biomonitoring data on
short-lived chemicals and disease present a unique set of challenges be-
cause blood or urine levels of biomarkers typically reﬂect recent expo-
sures that occurred just hours or at most days ago, and the timing of
the exposure relative to the biomarker sample collection is usually not
known. Yet most health outcomes of interest are chronic conditions
(e.g., obesity, hypertension, or measures of reproductive function) that
may require years to decades to develop. For this reason, evaluation of
causal hypotheses in studies thatmeasure short-lived chemicals is com-
plicated, and in some circumstances, may not be feasible. A critical and,
perhaps the only inarguable, property of a causal association is tempo-
rality, meaning that a claim of causation must be supported by an
observation of the putative causal exposure preceding the outcome
(Potischman and Weed, 1999; Rothman and Greenland, 2005; Weed,
1997; Weed and Gorelic, 1996).
Establishing temporality is only possible in “incidence” studies,
which identify health-related events such as new cases of disease at
the time of onset or a change in a health-related measure compared
to baseline (Pearce, 2012). Incidence studies may be experimental
(e.g., clinical trials) or observational (cohort or case–control with ascer-
tainment of incident cases). Regardless of design, however, the main
feature of incidence studies is the ability to establish the time of disease
onset (or at least the time of diagnosis), whichmay then allow for an as-
sessment of the sequence of exposure and outcome. In a situationwhen
exposure levels may rapidly change over time, a useful approach is a
longitudinal study that assesses the relation between repeated mea-
sures of exposure and repeated measures of health biomarkers.
Although the ability to establish the temporal relation is critical for
assessing causation, a separate study design issue in environmental
epidemiology research is the interval between the exposure and the
outcome under study. In order to use human biomonitoring data in
etiologic research, exposures should be measured at times which are
relevant for disease onset. While this is not a simple task, there are
examples of successful biomonitoring studies that have examined expo-
sures of persistent chemicals during relevant time windows and corre-
lated those exposures with development of speciﬁc adverse outcomes.For example, blood lead levels reﬂect exposures during the preceding
5–6 weeks; and well-conducted epidemiological studies have been
able to link the blood levels in children to adverse effects on cognitive
capacity (Lanphear et al., 2000). For chemicals with short half-lives,
however, the interval between the relevant exposure and disease devel-
opment is often difﬁcult to assess. Study design – along with exposure
misclassiﬁcation discussed later in this paper – are the most critical
and underexplored aspects of biomonitoring studies of short-lived
chemicals.
Establishing temporality is much more difﬁcult in a “prevalence”
study compared to an “incidence” study, which makes it challenging
to draw conclusions about causal associations. A typical prevalence
study relies on cross-sectional design, which ascertains the exposure
and disease information simultaneously (Rothman and Greenland,
1998). When research is focused on short-lived chemicals, many case–
control studies – even if they use incident cases – are difﬁcult to inter-
pret because the biomarker levels reﬂect recent exposures that typically
follow rather than precede disease onset. The notable exception is a
study that uses samples collected and stored for future use, as is done
in nested case–control or case–cohort studies (Gordis, 2008).
3.2.1.1. Short-lived chemical example. In a recent review of the epidemi-
ology literature on phthalate metabolites (Goodman et al., 2014) and
their association with obesity, diabetes, and cardiovascular disease,
most of the studies were cross-sectional in design. The study results
were inconsistent across outcomes and lack of temporality was identi-
ﬁed as a key limiting factor in the ability to discern relationships
between prior exposures to phthalate metabolites and consequent
health outcomes.
3.2.1.2. Study evaluation (Table 1). Tier 1 studies are incidence studies
that involve a follow-up time period or a longitudinal analysis of repeat-
edmeasures and allow the establishment of both the timeorder and the
relevant interval between the exposure and the outcome (Table 1). A
Tier 2 studywould include incidence studies in which exposure preced-
ed the outcome, but the speciﬁc relevant windows of exposure are not
considered. The least informative (Tier 3) studies are those that exam-
ine the association between current exposure (e.g., blood level of a
chemical) and frequently measured outcomes (e.g. BMI) that are likely
associated with chronic rather than acute exposures. (Note that this
evaluative criterion is not applicable to studies focused on exposure
only, such as those examining temporal or spatial relationships within
or across populations.)
3.2.2. Exposure variability and misclassiﬁcation
For many short-lived chemicals, there can be large intra-individual
temporal variability; attempting to ﬁnd associations between onemea-
sure of such a chemical with disease is not supportable. Differences in
biomonitored levels of short-lived chemicals due to changes in an
individual's diet, health, product use, activity and/or location are expect-
ed (Pleil and Sobus, 2013). As noted by Meeker et al. (2013): “Charac-
terizing temporal variability in exposure metrics, especially for
biomarkers of nonpersistent compounds…, is a critical step in designing
and interpreting an epidemiology study related to the potential for ex-
posure measurement error.”
Many published studies of short-lived chemicals seeking to estimate
chronic or average exposure are subject to error because they rely on
one measure of exposure using a one-time sample of urine or blood
(Goodman et al., 2014; LaKind et al., 2012b, 2014; Preau et al., 2010;
Wielgomas, 2013). The ability to estimate exposure can be improved
by taking multiple samples from the same individual at different times
to average temporal variations in the biomarker levels (NRC, 2006).
The reliability is typically measured by calculating the intra-class corre-
lation coefﬁcient (ICC). The ICC can be estimated by measuring the
chemical in repeated samples collected over several hours, days or
weeks and calculating the between-person variance divided by the
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proaching 1 suggests good reliability in estimating longer-term expo-
sure for the population from a single sample. Symanski et al. (1996)
used mixed-effects modeling to account for non-stationary behavior
in occupational exposures, and found that estimates of variance compo-
nents (used to compute ICC) may be substantially biased if systematic
changes in exposure are not properly modeled. The following question
still must be raised: if an ICC is developed from taking repeated samples
overweeks or evenmonths, will the value be relevant to exposures over
years,which is the timeframe for development ofmany chronic diseases
of interest? The research on this subject for many of the short-lived
chemicals of interest is currently undeveloped.
Another problemwith using a singlemeasure of a short-lived chem-
ical is error that may result in exposure misclassiﬁcation. Exposure
misclassiﬁcation occurs when the assigned exposures do not correctly
reﬂect the actual exposure levels or categories. It has been shown that
exposure misclassiﬁcation is difﬁcult to predict in terms of both di-
rection and magnitude (Cantor et al., 1992; Copeland et al., 1977;
Dosemeci et al., 1990; Sorahan and Gilthorpe, 1994; Wacholder
et al., 1995). The effect of exposure error and exposure misclassiﬁca-
tion on the dose–response relationship is problematic (Rhomberg
et al., 2011). Exposure misclassiﬁcation can occur frommany sources
of measurement error, including timing of sample collection relative
to when a critical exposure occurs. For example, many volatile or-
ganic compounds have half-lives on the order of minutes; exposures
may occur daily but for short time intervals. Thus, the concentration
of the biomarker of exposure is highly dependent on when the sam-
ple is collected relative to when the exposure occurred and may not
properly reﬂect the longer-term level in the body.
Use of multiple samples or prolonged (e.g., 24-h) sample collection
may help decrease error by diminishing the effects of temporal varia-
tion, study sub-population characteristics, and sample-related issues
(Scher et al., 2007). If error cannot be avoided (e.g., if all available sam-
pleswere obtained post-fast), it is important to assess accuracy of expo-
sure characterization by calculating sensitivities and speciﬁcities (Jurek
et al., 2006). Sensitivity is the probability of correctly classifying an indi-
vidual as having high level of exposure, if that person truly belongs in
the high exposure category. Speciﬁcity is the probability of correctly
assigning low exposure to a participant who truly has a low level of ex-
posure. Estimates of sensitivity and speciﬁcity may be calculated for a
single urine sample, using multiple samples per subject as gold stan-
dard, since the true sensitivity and speciﬁcity for manymeasures is un-
known. This can be achieved by randomly selecting a single sample
from among each individual's repeated samples collected over the
study (as demonstrated for phthalates in Adibi et al., 2008).
3.2.2.1. Short-lived chemical example. In a recent systematic review of the
epidemiology literature on phthalates and associationswith obesity, di-
abetes, and cardiovascular disease, Goodman et al. (2014) found that of
26 available studies, all but three relied on a single measure of
phthalates. Similarly, in a systematic review of BPA and obesity, diabe-
tes, and cardiovascular disease, LaKind et al. (2014) found that of 45
available studies, all but four relied on a single measure of BPA. Yet
the intra-individual variability for BPA is large (with ICCs ranging from
0.10 to 0.35) (Lassen et al., 2013; Teitelbaum et al., 2008), and multiple
measures of exposure are needed to describe a person's long-term ex-
posure. The ICCs for phthalates have been reported to be higher than
for BPA (e.g., ICC values range from 0.18 to 0.61 for mono-ethyl phthal-
ate, from0.21 to 0.51 formono-isobutyl phthalate, and from0.08 to 0.27
formono-(2-ethylhexyl) phthalate [reviewed in Goodmanet al., 2014]),
but intra-person variability is still large. Recently, Attﬁeld et al. (2014),
in a study of variability of urinary pesticide measures in children, ob-
served that a study with only a small number of samples from each
study participant “…may lead to a high probability of exposuremisclas-
siﬁcation by incorrect quantile assignment and offer little assurance for
correctly classifying the exposure into a speciﬁc category.”3.2.2.2. Study evaluation (Table 1). The above considerations permit
dividing the available body of literature into the following tiers
(Table 1). Tier 1 includes studies in which exposure assessment is
based on sufﬁcient number of samples per individual to estimate expo-
sure over the appropriate duration, or through the use of adequate
long-term sampling (e.g., multiple 24-hour urine collections). To be in-
cluded in Tier 1, studies should assess error by calculating measures of
accuracy (e.g., sensitivity and speciﬁcity) and reliability (e.g., ICC). It is
possible that for some chemicals, one sample may be sufﬁcient to fully
characterize exposure. If this is the case, a Tier 1 study needs to provide
evidence that errors of a single measurement can be considered sufﬁ-
ciently small. We realize this is not always feasible but there are circum-
stances where researcher will ﬁnd it necessary to perform a validation
study (Teeguarden et al., 2011). Tier 2 includes studies that use more
than one sample, but provide no rationale for their choice of the number
of measurements, and do not include an explicit evaluation of error. Tier
3 is reserved for studies in which exposure assessment is based on a sin-
gle sample without considering error.
3.3. General epidemiological study design considerations
In this section,we discuss aspects of study design that are not neces-
sarily speciﬁc to short-lived chemicals but are important in any assess-
ment of overall study quality. Some of these issues are more applicable
to those studies examining associations between exposure and health
outcome while others may be applied to studies focused on exposure
only.
3.3.1. Research rationale
This section applies to hypothesis-testing studies examining associ-
ations between biomonitoring data and health outcome data. A well-
formulated hypothesis arising from a clinical observation or from a
basic science experiment is the cornerstone of any epidemiological in-
quiry regardless of the speciﬁc research ﬁeld (Boet et al., 2012; Fisher
and Wood, 2007; Moher and Tricco, 2008). Current recommendations
in a variety of disciplines emphasize the importance of posing a research
question that is structured to convey information about the population
of interest, exposure (or corresponding marker) under investigation,
and the outcome of concern (Sampson et al., 2009;Walker et al., 2012).
Biomonitoring studies – and in particular those involving short-lived
chemicals where one sample can provide data on a multitude of
chemicals – often generate data that contain multiple variables with
an opportunity for multiple simultaneous hypothesis testing. This fea-
ture of biomonitoring studies can be viewed as a strength as in situa-
tions when signiﬁcant associations are observed for several related
outcomes (Lord et al., 2004); e.g., if a hypothesized obesogen exerts
similar effects on body mass index, waist circumference or percent
body fat. On the other hand, the ability to assess multiple exposure–
outcome associations complicates the interpretation of ﬁndings, par-
ticularly when dealing with previously collected data (Clarke et al.,
2003; Lee and Huang, 2005; Marco and Larkin, 2000). Among studies
that use previously collected data, it is important to distinguish those
that were guided by an a priori formulated hypothesis from those
that were conducted without a strong biological rationale, although
the latter category has been proven helpful in formulating new hy-
potheses (Liekens et al., 2011; Oquendo et al., 2012). A study with
a well-formulated hypothesis indicates that the study builds on previ-
ous knowledge, which is an important consideration for a WOE assess-
ment. Studies speciﬁcally designed to add to the existing knowledge
base can be more readily incorporated into WOE.
3.3.1.1. Study evaluation (Table 1). Studies evaluating an a priori formu-
lated hypothesis with a biomonitoring strategy speciﬁcally designed
to address this hypothesis should be considered the highest quality
(Tier 1). Tier 2 studies would be those using existing samples or data
to evaluate an a priori formulated hypothesis, where the biomonitoring
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the research relies on existing samples or data without a pre-speciﬁed
hypothesis or involves multiple simultaneous hypothesis testing. We
recognize that at present, the research rationale for most biomonitoring
studies involving short-lived chemicals will be described as Tier 3
studies.
3.3.2. Study participants
Evaluative schemes for participant selection apply to studies of both
persistent and short-lived chemicals. The goal of participant selection in
epidemiological research is to build a “bridge” between information
that is obtainable from the sample and information sought about
the target population (Kalsbeek and Heiss, 2000). The actual process
of selecting an unbiased population sample is an ongoing challenge
in case–control, longitudinal (cohort) and cross-sectional studies
(Vandenbroucke et al., 2007).
The issue of participant selection is not unique to epidemiological re-
search of short-lived chemicals. Yet biomonitoring studies may not pay
sufﬁcient attention to this problem. Previous reviews of biomonitoring
studies presented evidence that selection biasmay represent an impor-
tant threat to internal validity (Bull et al., 2006; Faust et al., 2004). The
same concerns are also applicable to biomonitoring studies of short-
lived chemicals such as phthalates (Durmaz et al., 2010; Wang et al.,
2013; Wirth et al., 2008).
3.3.2.1. Study evaluation (Table 1). Tier 1 studies include an unbiased se-
lection and/or follow up protocol with a high (e.g., over 80%) response
rate in cross-sectional or case–control studies, or low (e.g., less than
20%) loss to follow up in cohort studies. Tier 2 studies have an unbiased
selection/follow up protocol and a low (e.g., 50%–80%) response rate in
cross-sectional or case–control studies, or high (e.g., 20%–50%) loss to
follow up in cohort studies. Tier 3 studies are those that include less
than 50% of eligible participants, or fail to report methods of sample se-
lection and/or rates of non-response or loss to follow up. A study that
does not report this information should be assumed to be a Tier 3 study.
It is important to keep inmind that a low response rate or a high fre-
quency of loss to follow-up should not be equated with selection bias.
Selection bias occurs when the proportions of persons included in the
ﬁnal dataset (a.k.a. selection probabilities) differ by both exposure and
outcome (e.g., among exposed cases, non-exposed cases, exposed
non-cases and non-exposed non-cases.) Although the actual selection
probabilities are usually unknown, one can expect that in a study that
is missing only 10% of otherwise eligible participants, the magnitude
of possible bias is much lower than the corresponding magnitude in a
study that is missing 50% or more of its subjects.
3.3.3. Data analysis
Essential aspects of data analysis in epidemiologic research have
been reviewed elsewhere and are not speciﬁc to chemicals with short
physiologic half lives. However, for completeness of the proposed tiered
evaluative system, these considerations are described here in brief. The
overall analytic strategy in observational research depends on themain
goal of the study. Generally, statistical models fall into two categories—
predictive and explanatory (Shmueli, 2010). For predictive analysis, se-
lection of variables into the model is data-driven and may differ from
dataset to dataset. The goal of this approach is to maximize the model
ﬁt and a decision on whether to retain a particular covariate of interest
is based on statistical tests and goodness-of-ﬁtwithout a speciﬁed expo-
sure of interest (Bellazzi and Zupan, 2008). In an explanatory (hypoth-
esis testing) analysis, this approach may be inappropriate because it
may wrongly eliminate potentially important variables when the rela-
tionship between an outcome and a risk factor is confounded ormay in-
correctly retain variables that do not act as confounders (Kleinbaumand
Klein, 2002).
More importantly, for an explanatory model, which is focused on a
pre-deﬁned exposure–outcome association, inclusion and exclusion ofcontrol variables (confounders, mediators or effect modiﬁers) should
be driven, at least in part, by a priori reasoning (Beran and Violato,
2010; Concato et al., 1993; Hernan et al., 2002).
It is important to keep inmind that the results of observational stud-
ies are inevitably subject to uncertainty. This uncertainty may be attrib-
utable to various sources of unaccounted bias and to various data
handling decisions and assumptions. The magnitude of uncertainty
can be formally assessed through quantitative sensitivity analyses. The
methods of addressing residual bias through sensitivity analyses are
now well developed both in terms of basic theory (Greenland, 1996)
and with respect to practical applications (Goodman et al., 2007; Lash
and Fink, 2003; Maldonado et al., 2003). With respect to sensitivity
analyses of alternative decisions and assumptions, much can be learned
from previous experience in economics, exposure assessment and
quantitative risk analysis (Koornneef et al., 2010; Leamer, 1985;
Spiegelman, 2010).
3.3.3.1. Study evaluation (Table 1). Tier 1 studies include those that clear-
ly distinguish between causal and predictive models and demonstrate
adequate consideration of extraneous factors with assessment of effect
modiﬁcation and adjustment for confounders. To qualify for Tier 1, a
study should also perform formal sensitivity analyses. When consider-
ation of extraneous factors is considered adequate and themodel selec-
tion is appropriate, a studymay still be considered incompletewithout a
sensitivity analysis. Those studies are placed in Tier 2. Tier 3 studies are
those that did not adequately control for extraneous factors due to inap-
propriate methods of covariate selection, failure to consider important
confounders, or inability to take into account effect modiﬁcation.
The term “extraneous factors” describes participant characteristics
other than exposure and outcome of interest that need to be taken
into consideration in the design or the analysis phase of the study because
they may act as cofounders or effect modiﬁers or both (Kleinbaum et al.,
2007).
3.3.4. Reporting of results
We consider three aspects of reporting: transparency, multiple test-
ing and reporting bias.
3.3.4.1. Reporting transparency. As noted in the STROBE statement,
reporting of results should “ensure a clear presentation of what was
planned, done, and found in an observational study” (Vandenbroucke
et al., 2007). While these considerations are applicable to all studies,
there are aspects of study reporting that are of particular relevance to
biomonitoring research of short-lived chemicals.
Biological sample analyses are increasingly optimized for rapid anal-
ysis ofmultiple analytes in a single run. These developments in technol-
ogy increase the importance of complete reporting of the data including
a full list of exposure (and if applicable, outcome) biomarkers, aswell as
presentation of summary statistics, such as measures of central tenden-
cy and dispersion. Other critical information elements should include a
description of patterns and handling of missing data and measures
below LOD, all of which may inﬂuence interpretation of study results
(Albert et al., 2010; Barnes et al., 2008; LaKind et al., 2012b). In addition,
information should be provided on any power calculations used in
determining the number of study participants and on the exposure gra-
dient, which impacts the ability to identify signiﬁcant associations. Al-
though some of this information may not be included in the article
due to space constraints, it can be incorporated in supplementarymate-
rials or made available upon request.
3.3.4.2. Considerations for multiple testing. The main concern with multi-
ple hypothesis testing is increased likelihood of false positive (FP) re-
sults (Boffetta et al., 2008; Ioannidis, 2014; Jager and Leek, 2014;
Rothman, 1990; Sabatti, 2007). Others have argued that a problem of
FP results is no more important than the corresponding problem of
false-negatives (FN) (Blair et al., 2009). A decision of what type of
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speciﬁc, and should be made on a case-by-case basis. Recent advances
in genetic and molecular epidemiology led to the development of
novel approaches toward reducing the probability of FP (PFP) without
increasing the risk of FN results (Datta and Datta, 2005; Wacholder
et al., 2004). Evenmore recently, these approacheswere further extend-
ed to allow calculating the FP:FN ratio (Ioannidis et al., 2011).
3.3.4.3. Reporting bias.When evaluating a body of research for a meta-
analysis or WOE assessment, one must consider two speciﬁc sources
of bias that may inﬂuence both analysis and synthesis of the available
data: publication and outcome reporting bias. Publication bias is deﬁned
as the “tendency on the parts of investigators or editors to fail to publish
study results on the basis of the direction or strength of the study ﬁnd-
ings” (Dickersin and Min, 1993). A closely related concept is selective
within-study reporting (a.k.a. outcome reporting bias), which is deﬁned
as “selection on the basis of the results of a subset of the original vari-
ables recorded for inclusion in a publication” (Dwan et al., 2008).
Publication bias is not speciﬁc to research involving short-lived
chemicals. Outcome reporting bias, however, is potentially more prob-
lematic in studies of short-lived chemicals for reasons listed above. Spe-
ciﬁcally, better accessibility of sophisticated analytical platforms allows
more analytes to be measured in a larger number of samples.
3.3.4.4. Study evaluation. A Tier 1 study clearly states its aims and allows
the reader to evaluate the number of tested hypotheses (not just the
number of hypotheses for which a result is given). If multiple simulta-
neous hypothesis testing is involved, its impact is assessed, preferably
by estimating PFP or FP:FN ratio. There is no evidence of outcome
reporting bias, and conclusions do not reach beyond the observed re-
sults. In a Tier 2 study, the conclusions appear warranted, but the num-
ber of tested hypotheses is unclear (either not explicitly stated or
difﬁcult to discern) and/or there is no consideration of multiple testing.
Studies that selectively report data summaries and lack transparency in
terms ofmethods or selection of presented results are included in Tier 3.
4. Discussion/conclusions
The need for a systematic approach to evaluating the quality of envi-
ronmental epidemiology studies is clear. Two earlier efforts to develop
evaluative schemes focused on epidemiology research on environmen-
tal chemical exposures and neurodevelopment (Amler et al., 2006;
Youngstrom et al., 2011). Many of the concepts put forth in these pro-
posed schemes are valuable to any evaluation of study quality and com-
municating study results when considering biomonitoring of chemicals
with short physiologic half lives. For example, fundamental best prac-
tices/criteria proposed by Amler et al. (2006) include: a well-deﬁned,
biologically plausible hypothesis; the use of a prospective, longitudinal
cohort design; consistency of research design protocols across studies;
forthright, disciplined, and intellectually honest treatment of the extent
to which results of any study are conclusive and generalizable; conﬁne-
ment of reporting to the actual research questions, how they were test-
ed, and what the study found; recognition by investigators of their
ethical duty to report negative as well as positive ﬁndings, and the im-
portance of neither minimizing nor exaggerating these ﬁndings.
Chemicals with short physiologic half-lives present several impor-
tant challenges, including their presence in analytical laboratories and
sampling equipment, difﬁculty in establishing temporal order in cross-
sectional studies, short- and long-term variability in exposures and
biomarker concentrations, and a paucity of information on the number
of measurements is required for accurate exposure classiﬁcation. The
BEES-C instrument is designed to evaluate these issues within a study
or proposal.
We recognize that the development of an evaluative tool such as
BEES-C is neither simple nor non-controversial, and we further expect
that this will be an iterative process, similar to the data quality schemethat has been part of CONSORT and other existing methods or evaluat-
ing quality of clinical data. We also note that this type of evaluative
scheme is not useful for exploratory research; rather, the focus here is
on designing and identifying those studies that have the greatest utility
for furthering our understanding of associations between exposure to
chemicals with short half lives and adverse health outcomes. We hope
and anticipate that the instrument developed from this workshop will
initiate further discussion/debate on this topic.Conﬂict of interest
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